Global inflation keeps investors on edge, yet Switzerland’s strongest quarterly GDP reading since 2021 shows that companies with healthy balance sheets and real earnings power can still grow. That resilience is the heart of the Healthy high growth potential screener. It filters for stocks that analysts expect to grow earnings and that sit on solid financial foundations. This article highlights three of the most compelling candidates.

The stocks covered below are just a sample, and the full screen surfaced 1,526 more companies with equally compelling earnings growth and balance sheet stories that are not covered in this article. To identify and analyze the highest conviction ideas that fit your own criteria, head straight into the Healthy high growth potential screener.

Cloudflare (NET)

Overview: Cloudflare is a cloud services company that helps businesses run faster and more securely on the internet by protecting websites and applications, managing traffic, and securing remote access for employees and devices. Its platform sits between users and a company’s infrastructure, blocking attacks, speeding up content delivery, and supporting AI and developer workloads.

Operations: Cloudflare generates about US$2.5b in revenue from its Internet Telephone segment, with the United States, Europe, Middle East and Africa, Asia Pacific, and the Rest of the World all contributing meaningful sales.

Market Cap: US$110.9b

Cloudflare sits at the intersection of cybersecurity, AI infrastructure, and developer tools. Many investors pay attention to it despite the company currently reporting losses and a very high P/S multiple. The company is exposed to rising demand for zero trust security, AI related workloads, and its Workers developer platform, while large enterprise and government customers deepen their spending. At the same time, heavy investment in AI traffic, mixed profitability in recent quarters, and competition from hyperscalers create execution risk. With funding from sizeable convertible debt and a rich valuation, you need to decide whether the growth story still leaves enough potential opportunity.

Cloudflare’s high growth story and rich P/S multiple raise a simple question. Is the current excitement justified by the earnings path analysts see ahead, or missing a key twist in the analyst forecasts for Cloudflare?

Build your own high growth and quality shortlist

Cloudflare and the two other stocks in this article all came from a single Simply Wall St screen, but the real edge is in setting your own rules. Use our flexible Screener to combine filters like growth, valuation, balance sheet strength and risks, or start with any of our curated Investing Ideas for ready made shortlists.

Liquidia (LQDA)

Overview: Liquidia is a biopharmaceutical company focused on treatments for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension and related lung conditions, using its PRINT particle engineering technology to deliver treprostinil through inhaled dry powder, injections, and an investigational liposomal formulation. It partners with groups such as Pharmosa Biopharm, Vectura, major pharmaceutical companies, and academic institutions to develop and commercialize these therapies.

Operations: Liquidia generates about US$451 million in revenue from its Pharmaceuticals segment, all from the United States.

Market Cap: US$6.45b

Liquidia has quickly become a stock to watch for investors interested in rare disease treatments, supported by YUTREPIA’s rapid prescription uptake and a pipeline led by L606 that both target pulmonary hypertension using the same core treprostinil approach. Analyst forecasts point to earnings and revenue growth, improving profitability, and a solid cash position, which have attracted attention. At the same time, the company faces meaningful risks related to patent disputes, capacity expansion that depends on sustained demand, and reliance on a single drug class. For investors willing to weigh those legal and execution questions against the potential of a focused prostacyclin franchise, Liquidia represents a concentrated story in rare cardiopulmonary disease treatment that extends beyond the headline numbers.

Liquidia’s rare disease story is accelerating around treprostinil and a focused pulmonary hypertension pipeline, yet the market may still be missing what sits beneath the headline prescription and cash story in the analysis report for Liquidia

Cerebras Systems (CBRS)

Overview: Cerebras Systems builds an AI compute platform around a single wafer scale chip designed to run demanding inference and generative AI workloads much faster than conventional GPU clusters. It sells full rack systems and cloud capacity to hyperscalers, AI labs, enterprises and governments that need ultra fast model serving at data center and supercomputer scale.

Operations: Cerebras Systems generates about US$681 million in revenue from its Semiconductors segment.

Market Cap: US$54.9b

Investors watching the race to power AI inference at scale may want to have Cerebras Systems on the radar. The company pairs a wafer scale chip and cloud offering with a US$24.6b contracted backlog and partnerships spanning OpenAI, AWS, AMD and major enterprises. Analyst forecasts indicate revenue growth of about 44.5% a year and a potential shift from losses to profitability within 3 years. At the same time, the stock has a history of sharp share price swings, depends heavily on a few large customers, and faces margin pressure as it builds out capacity and funds 100% of liabilities through external borrowing. For investors who can handle volatility, the combination of these factors and the company’s position in AI infrastructure may be worth closer consideration.

Cerebras Systems sits at the center of the AI infrastructure story, yet the real twist may lie in what analysts expect next for its growth curve. Get the full picture in the analyst forecasts for Cerebras Systems

Seeking Alternatives Before Momentum Runs?

Fresh stock ideas can move from under the radar to fully caught in the momentum rush quickly. Check these curated shortlists before the crowd and act now.

• Spot cash rich companies holding up when others are dropping by scanning our curated list of solid balance sheet and fundamentals (49 results). It filters for resilience while it still matters.
• Ride the AI build out before it goes from quiet accumulation to full breakout by reviewing the hand picked 55 AI infrastructure stocks powering data centers and model training.
• Position ahead of shifting energy priorities with a focused 91 nuclear energy infrastructure stocks that zeroes in on companies tied to power grid upgrades and nuclear infrastructure momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.